🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  2. Everolimus

    Jazz Pharmaceuticals Ireland Limited

    Diffuse Intrinsic Pontine Glioma

    phase 3 small molecule active

    1 trial

  3. Everolimus

    United Therapeutics Europe Ltd

    Pediatric Heart Transplantation

    phase 3 small molecule active

    1 trial

  4. Everolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  6. Evinacumab

    Ultragenyx UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  7. Evolocumab

    Amgen

    Severe Familial Hypercholesterolemia

    phase 3 mab completed

    1 trial

  8. Exa-cel

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  9. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  10. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  11. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  12. Exparel

    Pacira Ireland Limited

    Chronic Shoulder Pain

    phase 3 small molecule active

    1 trial

  13. Exparel

    Pacira Ireland Limited

    Back Pain

    phase 3 small molecule active

    1 trial

  14. Exparel

    Pacira Ireland Limited

    Mammaplasty

    phase 3 small molecule completed

    1 trial

  15. Exparel

    Pacira Ireland Limited

    Postoperative Pain Management

    phase 3 small molecule completed

    3 trials

  16. Exparel

    Pacira Ireland Limited

    Lower Extremity Surgery

    phase 3 small molecule completed

    1 trial

  17. Exparel Injectable Product

    Pacira Ireland Limited

    Coronary Artery Disease

    phase 3 small molecule completed

    1 trial

  18. Experimental: Tezepelumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  19. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

  20. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  21. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  22. Extended treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 small molecule completed

    1 trial

  23. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  24. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources